Data from the phase 2/3 QUILT-3.032 trial showed that adding N-803 to BCG met the primary end point of disease-free survival in patients with BCG-unresponsive, high-grade non–muscle-invasive bladder cancer and papillary disease.
“In our analysis, the highest ranked treatment strategy was the combination of standard of care systemic therapy, an AR pathway inhibitor, and prostate radiotherapy,” says…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Colin Goudelocke, MD, offers insight on 2 abstracts from the 2024 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting.
“I don’t think anybody, at least in our Mayo Clinic practices, is ever doing anything other than apical release HoLEPs these days,” says Daniel J.…
“As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies…
“The da Vinci 5, or DV5, system is the next evolution of robotic surgery,” says Jaschar Shakuri-Rad, DO, FACOS.
“I think the main question is just how to disseminate this information. Obviously, there’s a huge need,” says Megan S. Bradley, MD.
The IND will initiate the launch of a phase 3 study to explore the safety and efficacy of UGN-103 in patients with low-grade, intermediate-risk NMIBC.
The study is exploring the small activating RNA therapy RAG-01 in patients with BCG-unresponsive non–muscle-invasive bladder cancer.
“Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe,” says Bob Yang, MBBS, FRCS.
